Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShunfeng HuBLBeibei Lv

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows polatuzumab vedotin improves complete response rates in diffuse large B-cell lymphoma patients, suggesting better outcomes.

Key Points

  • This research aims to evaluate the efficacy and safety of polatuzumab vedotin-based regimens for treating diffuse large B-cell lymphoma (DLBCL).
  • Retrospective real-world study conducted on 109 patients with clinically confirmed DLBCL
  • Adverse events were assessed using NCI CTCAE v4.03
  • Subgroup analyses conducted to evaluate treatment outcomes based on demographic and clinical factors.
  • 40.6% of patients achieved complete response, while 33.7% had partial response, resulting in an overall response rate of 74.3%
  • Patients treated for more than 3 months had significantly higher complete response rates
  • Adverse events were relatively mild, with few grade 3 toxicities reported.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d524https://doi.org/10.1182/blood-2025-7199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China2025
  2. 2Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study2025
  3. 3Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  4. 4A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  5. 5Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024)2025